Moomoo AI 已提取核心信息
Avalo Therapeutics, Inc. has successfully regained compliance with the Nasdaq Capital Market's minimum bid price requirement, according to a notification received from Nasdaq on January 30, 2024. The company had previously been warned on August 8, 2023, that its common stock had been trading below the $1.00 minimum bid price for 30 consecutive business days, violating Nasdaq's Listing Rule 5550(a)(2). In response, Avalo Therapeutics executed a reverse stock split on December 28, 2023, which resulted in the stock price remaining above $1.00 since December 29, 2023. Despite regaining compliance, Nasdaq has placed the company under a one-year mandatory panel monitor starting from January 30, 2024. Should Avalo Therapeutics fall below the bid price requirement again within this period, it will not be allowed to submit a compliance plan and could face delisting without the possibility of an extension or cure period. The company would then have the right to request a hearing with a Nasdaq panel to address the issue.
Avalo Therapeutics, Inc. has successfully regained compliance with the Nasdaq Capital Market's minimum bid price requirement, according to a notification received from Nasdaq on January 30, 2024. The company had previously been warned on August 8, 2023, that its common stock had been trading below the $1.00 minimum bid price for 30 consecutive business days, violating Nasdaq's Listing Rule 5550(a)(2). In response, Avalo Therapeutics executed a reverse stock split on December 28, 2023, which resulted in the stock price remaining above $1.00 since December 29, 2023. Despite regaining compliance, Nasdaq has placed the company under a one-year mandatory panel monitor starting from January 30, 2024. Should Avalo Therapeutics fall below the bid price requirement again within this period, it will not be allowed to submit a compliance plan and could face delisting without the possibility of an extension or cure period. The company would then have the right to request a hearing with a Nasdaq panel to address the issue.
根据纳斯达克于2024年1月30日收到的通知，Avalo Therapeutics, Inc.已成功恢复对纳斯达克资本市场的最低出价要求的遵守。该公司此前曾在2023年8月8日受到警告，其普通股连续30个工作日的交易价格低于1.00美元的最低出价，违反了纳斯达克的上市规则5550（a）（2）。作为回应，Avalo Therapeutics于2023年12月28日进行了反向股票拆分，导致股价自2023年12月29日以来一直保持在1.00美元以上。尽管恢复了合规性，但纳斯达克已从2024年1月30日起将该公司置于为期一年的强制性小组监督之下。如果Avalo Therapeutics在这段时间内再次跌破出价要求，它将不允许提交合规计划，并且可能在没有延期或治愈期的情况下面临退市。然后，该公司将有权要求与纳斯达克小组举行听证会以解决该问题。
根据纳斯达克于2024年1月30日收到的通知，Avalo Therapeutics, Inc.已成功恢复对纳斯达克资本市场的最低出价要求的遵守。该公司此前曾在2023年8月8日受到警告，其普通股连续30个工作日的交易价格低于1.00美元的最低出价，违反了纳斯达克的上市规则5550（a）（2）。作为回应，Avalo Therapeutics于2023年12月28日进行了反向股票拆分，导致股价自2023年12月29日以来一直保持在1.00美元以上。尽管恢复了合规性，但纳斯达克已从2024年1月30日起将该公司置于为期一年的强制性小组监督之下。如果Avalo Therapeutics在这段时间内再次跌破出价要求，它将不允许提交合规计划，并且可能在没有延期或治愈期的情况下面临退市。然后，该公司将有权要求与纳斯达克小组举行听证会以解决该问题。
有用
没用